Summanr P450 reductase (NADPH:cy-tochrome P450 reductase. EC 1.6.2.4) is known to be important in the reductive activation of the benzotriazene-di-N-oxide tirapazamine (SR 4233). Using a panel of six human breast adenocarcinoma cell lines we have examined the relationship between P450 reductase activity and sensitivity to tirapazamine. The toxicity of tirapazamine was found to correlate strongly with P450 reductase activity following an acute (3 h) exposure under hypoxic conditions, the drug being most toxic in the cell lines with the highest P450 reductase activity. A similar correlation was also observed following a chronic (96 h) exposure to the drug in air but not following acute (3 h) exposure in air. We have also determined the ability of lysates prepared from the cell lines to 'metabolise tirapazamine to its two-electron reduced product, SR 4317. under hypoxic conditions using NADPH as an electron donor. The rate of SR 4317 formation was found to correlate both with P450 reductase activity and with sensitivity to tirapazamine. the highest rates of SR 4317 formation being associated with the highest levels of P450 reductase activity and the greatest sensitivity to the drug. These findings indicate a major role for P450 reductase in determining the hypoxic toxicity of tirapazamine in breast tumour cell lines.
The presence of regions of low oxygen tension in a variety of human solid tumours is now well established (Gatenby et Hockel et al., 1991 Lartigau et al.. 1992 ) and this hypoxia can predispose to failure of some treatments with radiotherapy (Gatenby et al.. 1988; Hockel et al.. 1993 : Okumneff et al.. 1993 . The resistance of hypoxic cells to radiation has long been recognised in experimental systems Rockwell, 1987: Rockwell and Moulder. 1990) , and methods designed to overcome this resistance have included the development of hypoxic cell radiosensitisers (Adams, 1976: ) and more recently the combination of nicotinamide and carbogen (Chaplin et al.. 1991 ). An alternative strategy has been to develop agents that selectively kill hypoxic cells (Adams and Stratford et al., 1986; Zeman et al., 1986; Kennedy, 1987) . This approach involves the exploitation of various biochemical processes that can result in selective reductive activation of drugs at low oxygen tensions (Kennedy. 1987; Workman. 1992; Workman and Stratford, 1993) . In principle, this concept was first proposed in the context of quinone bioreductive drugs, with the notion that the low levels of oxygen in solid tumours could allow reductive activation of a drug to give a product which was more toxic than the parent compound (Lin et al., 1972) . Subsequently. agents have been identified that are substantially more toxic to hypoxic compared with oxic cells and this is the basis for their tumour selectivity (Adams and Stratford and Stephens. 1989 .) Classes of compound that are in, or are about to enter, clinical trial as bioreductive drugs include (1) RB6145, the lead compound from a series of dual-function, alkylating nitroimidazoles (Cole et al., 1990 (Cole et al., , 1991 (Cole et al., , 1992 Jenkins et al., 1990) (2) quinones such as the mitomycin C analogue porfiromycin (Rockwell et al., 1988) and the indoloquinone E09 (Hendriks et al.. 1993); and (3) the benzotnrazene-di-N-oxide tirapazamine (SR4233, (Brown and Lemmon, 1990; Brown, 1993) .
As indicated above, the major rationale for the development of bioreductive drugs has been the presence of tumour hypoxia. However, for these agents to be effective they require metabolic activation. catalysed by the cellular complement of reductase enzymes. These can include isozymes of the P450 system, cytochrome P450 reductase, cytochrome b5 reductase, xanthine oxidase etc (Walton et al., 1989; Workman. 1992; Hodnick and Sartorelli, 1993) . Therefore, it has been proposed that hypoxic cells could be more effectively targeted if differences in the levels of reductases in vanrous cell types were taken into account in order to direct appropriate agents to particular human tumours based on their enzymology (Workman and Walton, 1986; Workman and Stratford, 1993; Workman, 1994) .
The potential usefulness of the 'enzyme-directed' approach to bioreductive drug development has been very clearly demonstrated with the mitosense E09. The toxicity of this agent in air is highly dependent on the cellular expression of the obligate two-electron reductase, DT-diaphorase, (Robertson also be catalysed by cytochrome P450 reductase (Bailey et al., 1994) an enzyme which has been shown to play an important role in the metabolism of 2-nitroimidazoles (Walton and Workman, 1987) and N-oxides such as tirapazamine (Walton et al., 1989) .
In previous studies on the metabolism of tirapazamine using mouse and rat liver microsomes (Walton et al., 1989 (Walton et al., , 1992 Lloyd et al., 1991) and tumour cell lysates (Wang et al., 1993) it was shown that both cytochrome P450 and cytochrome P450 reductase contribute to the overall reduction of tirapazamine to its two-electron reduced product SR 4317. Cytochrome P450 is dependent upon the presence of cytochrome P450 reductase for its catalytic activity (Peterson and Prough, 1986) . Hence, P450 reductase will play both direct and indirect roles in the reduction of tirapazamine. Moreover, tirapazamine is reduced by purified rat liver cytochrome P450 reductase (Walton et al., 1989, Cahill and White, 1990) leading to the production of strand breaks in co-incubated plasmid DNA (Fitzsimmons et al., 1994) . Therefore, the aim of this work was to assess the likely importance of P450 reductase activity for determining the sensitivity of tumour cells to tirapazamine. To do this we have measured P450 reductase activity in a panel of six human breast adenocarcinoma cell lines, and compared this with their sensitivity to tirapazamine under hypoxic and aerobic conditions. Given the role of P450 reductase in reducing tirapazamine, we have also determined the ability of the different cell lines to metabolise tirapazamine to its reduced product SR 4317 un*er hypoxic conditions. (Seng and Ley, 1972 Table I . The enzyme activity in the breast cancer cell lines covers a 6-fold range. This contrasts with the activity of the reductase DT-diaphorase in these cell lines, which varies by a factor of 260, the highest expressor being ZR-75 and the lowest MDA-23 1 cells . We have shown previously that the toxicity of tirapazamine in breast and lung cancer cells following a 96 h aerobic exposure does not depend on DT-diaphorase activity (Patterson et al., 1994) . However, as can be seen in Figure 2 , there is a clear relationship between P450 reductase activity and tirapazamine toxicity in breast cancer cells following chronic (96 h) exposure in air. The highest toxicity (lowest value of IC50) occurs in the cell line with highest activity of P450 reductase (SKBr3). The value of slope derived from these data is-1.6 ± 0.3 (P= 0.006).
The importance of P450 reductase in the activation and toxicity of tirapazamine in the breast cancer cells has been characterised further by carrying out acute (3 h) exposure to drug under aerobic and hypoxic conditions. The dependence of IC50 on P450 reductase activity is shown in Figure 3 .
Under hypoxic conditions there is a highly significant relationship between intracellular enzyme activity and drug tox- P450 reductase has previously been shown to play an important role in the metabolism of tirapazamine (Walton et al., 1989 (Walton et al., , 1992 Lloyd et al., 1991; Wang et al., 1993) . Furthermore, the rate of metabolism has been linked to cytotoxic effciency under anaerobic conditions (Biedermann et al., 1991) . In order to determine whether P450 reductase is a major factor contributing to the metabolism of tirapazamine in breast cancer cells, we have measured the rate at which cell lysates reduce tirapazamine to its two-elctron reduced product, SR 4317 under hypoxic conditions. The structures of these compounds are given in Figure 5 . No formation of the deoxygenated four-eectron reduced product, SR 4330, was deteced in these experiments. These rates of formation of SR 4317 are given in Table I and a plot of P450 reductase activity in the breast cancer cell lines vs the rate of SR 4317 formation catalysed by lysates of each cell line, with NADPH provided as the electron source, is given in Figure 6 . It can be seen from these data that there is a strong correlation (slope value=1.10±0.23; P=0.009) between P450 reductase activity and SR 4317 formation, with higher values of enzyme activity resulting in greater rates of metabolism. When similar experiments were carried out in air, no metabolism was detected.
Previous studies have shown that tirapazamine is reductively metabolised to SR 4317 by purified rat liver NADPH: (Cahill and White. 1990; Fitzsinmons et al.. 1994 In the presence of P450 reductase. tirapazamine (SR 4233) will be subject to one-electron reduction to give the radical anion (SR 4233-). which in its protonated form has been identified as a nitroxide radical (Lloyd et al.. 1991 68.5) are most likely to be explained by the effects of redox cycling which will occur in air. During this process SR 4233-will be formed following one-electron reduction of tirapazamine. catalysed by P450 reductase. In the presence of oxygen the reduced product will be back-oxidised to tirapazamine. with the concomitant production of oxygen radicals. Thus. in air, cellular damage may be mediated by both superoxide radicals and SR 4233-. Relatively high concentrations of tirapazamine were used during the acute exposure to air. which is likely to result in the formation of sufficiently high concentrations of oxygen radicals to overwhelm cellular antioxidant defence mechamsms. Thus, the variation in cellular sensitivity to tirapazamine following acute exposure in air may well reflect variations in the tolerance of the different cell types both to oxidative damage and to damage by SR 4233 -. thereby explaining the apparent lack of a relationship between the drug toxicity and P450 reductase activity under these conditions. Evidence suggesting that the type of damage occumrng in cells following acute (3 h) exposure to tirapazamine in either air or nitrogen can be different. comes from studies comparing drug toxicity in a V79 cell line and a DNA repair-deficient mutant line derived from it (Keohane et al.. 1990 ). V79 and irs-I cells have similar sensitivities to tirapazamine in hypoxia whereas, in air irs-1 cells are 10-fold more sensitive (as measured by values of ICs9). The irs-I cells are radiation sensitive and are defective in the fidelity of DNA strand break repair. If it is assumed that the two cell lines have a similar ability to metabolise tirapazamine i.e., similar P450 reductase activities, then the difference in sensitivities between V79 and irs-I cells observed in air but not in nitrogen would reflect differences in the damage caused under these conditions. That is. in hypoxia. the damage is caused by P450 reductase-mediated formation of tirapazamine radicals which can interact with DNA. whereas, following acute exposures in air, cells are additionally damaged by oxygen radicals. Support for the latter is indicated by the finding that the addition of metal chelators can protect cells against the toxic effects of tirapazamine in air but not in nitrogen (Herscher et al.. 1994) .
Following chronic (96 h) exposure of cells to tirapazamine in air. a relationship between P450 reductase activity and drug toxicity is observed. However, the concentrations of drug used in these experiments were 10-to 50-fold lower than those used in the acute (3 h) aerobic experiments. Therefore, it might be expected that the concentrations of oxygen radicals formed by redox cycling are likely to be low enough to be accommodated by the cellular antioxidant defence mechanisms. Thus. for this treatment condition, toxicity will be due predominantly to damage caused by Lysates derived from the breast cancer cells have been assayed for their ability to metabolise tirapazamine to SR 4317 under hypoxic conditions and this is shown to depend on P450 reductase activity ( Figure 5) (1991) has shown that the hypoxic toxicity of tirapazamine correlates with the overall rate of metabolism of the parent drug. In a mouse and a human sarcoma cell line, DTdiaphorase and cytochromes P450 were shown to contribute to the metabolism of tirapazamine under hypoxic conditions but no evidence was provided for the role of P450 reductase in these cells (Wang et al., 1993) . Our previous studies on DT-diaphorase clearly indicate that this enzyme does not play an important role in determining sensitivity to tirapazamine in air or hypoxia in the breast cancer cells (Patterson et al., 1994) . The role of P450 isozymes is less clear, particularly since cells in culture lose their ability to regulate the expression of P450 genes (Paine, 1990) . From studies using chemical and antibody inhibitors in enzyme-induced mouse liver microsomes, it has been suggested that Cyp2b and Cyp2c can contribute to tirapazamine reduction (Riley et al., 1993) . However, this has yet to be linked to toxicity. In clinical samples of breast tumour tissue only the presence of CYPIA has been demonstrated unequivocally (Murray et al., 1991) , whereas in breast xenografts in mice CYPs 2A, 2B, 2C, 3A and 4A have been detected, but only to a significant extent after enzyme induction (Smith et al., 1993) .
In conclusion, we have demonstrated that NADPH:P450 reductase plays a major role in determining the hypoxic toxicity of tirapazamine in breast cancer cells. This provides an example of the enzyme-directed approach to bioreductive drug development, and we are currently evaluating the generaity of this approach for tirapazamine in other tumour types.
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